NCT07187063NARecruiting

Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer

Lahey Clinic

Start Date

1/1/2025

Completion Date

1/1/2029

Summary

The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less frequent cystoscopy surveillance.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * AUA high-risk bladder cancer1 * Received induction BCG or gemcitabine/docetaxel * Negative initial post-induction therapy assessment (negative cytology and cystoscopy +/- biopsy) Exclusion Criteria: * High-risk NMIBC within 3 years * Prior induction intravesical therapy * Variant histology * Concurrent upper tract disease

Interventions

DIAGNOSTIC_TEST

UroAmp Test (Convergent Genomics, Inc.)

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Non-muscle Invasive Bladder Cancer (NMIBC)

Locations

Lahey Hospital and Medical Center

Burlington, Massachusetts 01805

United States